Aernoud Fiolet

79 Colchicine in Stable Coronary Artery Disease failed to reduce the incidence of restenosis at 6 months. 36 The second involved 196 patients with diabetes treated with bare-metal stents; this study showed that colchicine 0.5 mg BID halved the rate of angiographic in-stent restenosis (16% vs 33%; P = 0.007) at 6 months. 37 Together, these results might suggest that colchicine has no effect on early restenosis related to elastic recoil after balloon angioplasty but that it may prevent neo-intimal hyperplasia that causes early in-stent stenosis, as has been described in animal models. 38 Table I. Retrospective studies on colchicine and cardiovascular outcomes. Study Crittenden et al., 2012 30 Solomon et al., 2015 31 Study Design Retrospective cohort study Retrospective matched cohort study Sample Size 1288 (576 colchicine, 712 no colchicine) 1002 (501 colchicine, 501 no colchicine) Population Gout patients Gout patients Primary Outcome Components and Assessment Myocardial infarction (ICD-9 coding) Myocardial infarction, stroke, transient ischemic attack (ICD-9 coding) Primary Outcome, Crude Association Incidence 1.2% vs 2.6% (RR, 0.46; P = 0.03) Incidence rate ratio, 0.44; 95% CI, 0.27–0.68 Primary Outcome, Adjusted Association NA HR, 0.51; 95% CI, 0.30–0.88 Myocardial Infarction, Crude Association Incidence 1.2% vs 2.6% (RR, 0.46; P = 0.03) Incidence rate ratio, 0.52; 95% CI, 0.29–0.92 Myocardial Infarction, Adjusted Association NA NA All-cause Mortality, Crude Association Incidence 3.9% vs 5.1% (RR, 0.76; P = 0.18) Incidence rate ratio, 0.55; 95% CI, 0.39–0.79 All-cause Mortality, Adjusted Association NA HR, 0.55; 95% CI, 0.35–0.85 Confounding Factors Taken Into Account None Several* * Age, sex, race, history of cardiovascular disease, diabetes, hypertension, statin use, aspirin use, antihypertensive use, smoking, body mass index, NSAID use or co-inhibitors, oral steroids, allopurinol, and chronic kidney disease or end-stage renal disease Abbreviations: CI, confidence interval. HR, hazard ratio. ICD-9, International Classification of Diseases, Ninth Revision. NA, not available. RR, relative risk